Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
70
datasets available to search
ShareScore release 0.9.0
Dataset results
70 results for “hepatotoxicity”
Suplementary material: Towards uncoding hepatotoxicity of approved drugs through navigation of multiverse and consensus chemical spaces
<p>Supplementary material: "Towards uncoding hepatotoxicity of approved drugs through navigation of multiverse and consensus chemical spaces"</p>
Underlying data for "Microscale 3D Liver Bioreactor for In Vitro Hepatotoxicity Testing under Perfusion Conditions"
<p>Underlying data for the paper "Microscale 3D Liver Bioreactor for In Vitro Hepatotoxicity Testing under Perfusion Conditions" published in the journal <em>Bioengineering</em>.</p>
The essential oil of Polygonum minus modulating cisplatin-induced hepatotoxicity through inflammatory and apoptotic pathway
<p>Oxidative stress, inflammation and apoptosis are thought as primary mediators of cisplatin-induced hepatotoxicity. The objective of this study was to determine the protective effect of <em>Polygonum minus</em> essential oil in cisplatin-induced hepatotoxicity. A total of forty-two male rats were randomly divided into seven groups: control, cisplatin, positive control β-caryophyllene 150 mg/kg (BCP), PmEO 100 mg/kg + cisplatin (PmEO100CP), PmEO 200 mg/kg + cisplatin (PmEO200CP), PmEO 400 mg/kg + cisplatin (PmEO400CP) and PmEO 400 mg/kg (PmEO400). Rats in the BCP, PmEO100CP, PmEO200CP, PmEO400CP and PmEO400 group received respective treatment orally for 14 consecutive days prior to cisplatin injection. All animals except for those in the control group and PmEO400 were administered with a single dose of cisplatin (10 mg/kg) intraperitoneally on day 15 and were sacrificed on day 18. PmEO100CP pretreatment protected against cisplatin-induced hepatotoxicity by decreasing CYP2E1, malondialdehyde, 8-OHdG and protein carbonyl which was accompanied by increased antioxidant status as compared to cisplatin alone group. PmEO100CP pretreatment also attenuated changes in liver inflammatory markers. PmEO100CP administration also reduced cisplatin-induced apoptosis. In conclusion, our results suggested that <em>P. minus</em> essential oil at a dose of 100 mg/kg may protect against cisplatin-induced hepatotoxicity possibly via inhibition of oxidative stress, inflammation and apoptosis.</p>
Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
<p><span>Adverse events(AEs) related to hepatotoxicity have been reported in patients treated with immune checkpoint inhibitors (ICIs). As the number of adverse events increases, it is necessary to assess the differences in each immune checkpoint inhibitor regimen. The purpose of this study was to examine the relationship between ICIs and hepatotoxicity in a scientific and systematic manner. Data were obtained from the FDA Adverse Event Reporting System database (FAERS) and included data from the first quarter of 2014 to the fourth quarter of 2021. Disproportionality analysis assessed the association between drugs and adverse reactions based on the reporting odds ratio (ROR) and information components (IC). 9,806 liver adverse events were reported in the FAERS database. A strong signal was detected in older patients (≥65 years) associated with ICIs. Hepatic adverse events were most frequently reported with Nivolumab (36.17%). Abnormal liver function, hepatitis, and autoimmune hepatitis were most frequently reported, and hepatitis and immune-mediated hepatitis signals were generated in all regimens. In clinical use, patients should be alert to these adverse effects, especially in elderly patients, who may be aggravated by the use of ICI.</span></p>
Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
Open the record for dataset details and reuse information.
Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity
ClinicalTrials.gov study NCT01456845. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity
ClinicalTrials.gov study NCT02353455. IPD Sharing: Not stated. Countries: 5. Publications: 15.
The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs
ClinicalTrials.gov study NCT01800487. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Acetaminophen-induced Hepatotoxicity in Chronic Alcohol Abusers
ClinicalTrials.gov study NCT00137059. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
ClinicalTrials.gov study NCT05501899. IPD Sharing: NO. Countries: 1. Publications: 12.
Data from: Hepatotoxicity of isotretinoin in patients with acne and Gilbert's syndrome: comparative study
Objectives: The objective of our follow-up study is to evaluate liver function tests (LFTs) and lipid profiles in patients with Gilbert's syndrome treated with isotretinoin because of severe acne. Setting: Dermatology outpatient clinics of three regional hospitals of Jaén (Spain). Participants: Over 4 years, we included all patients diagnosed with severe acne. Only 37 patients were identified, of which 11 had Gilbert's syndrome. Interventions: All patients were treated with isotretinoin and followed-up in our outpatient clinics after 10 and 20 weeks. Patients were subjected to an interview questionnaire which included data on age, gender, complete blood count, coagulation profile, fasting blood glucose, LFTs and lipid profiles. Data and results of patients with severe acne and Gilbert's syndrome were compared with those of 26 patients with only severe acne (control group). Primary: outcome Blood analyses were repeated in the follow-up visits. Results: In patients with Gilbert's syndrome, bilirubin levels showed substantial decrease over the 20-week follow-up, with more decrease after 10 weeks. None of the control group patients had significant increase in total bilirubin levels after 10 and 20 weeks of follow-up. Liver enzymes were maintained within normal levels in both groups. Both study groups did not show significant pathological increase in lipid profile levels. LDL levels were increased in the two study groups, but this increase was less substantial in patients with Gilbert's syndrome. Conclusions: Our preliminary results suggest that oral isotretinoin could be an effective, safe treatment for patients with Gilbert's syndrome, and may lower bilirubin levels in the first 10 weeks of treatment. Limitations of the study include the small numbers of participants and the fact that it is restricted to one region of Spain.
Figure 2 from: Mitkov J, Kondeva-Burdina M, Zlatkov A (2019) Synthesis and preliminary hepatotoxicity evaluation of new caffeine-8-(2-thio)-propanoic hydrazid-hydrazone derivatives. Pharmacia 66(3): 99-106. https://doi.org/10.3897/pharmacia.66.e37263
Figure 2 Effect of the hydrazid-hydrazones 6a–i, administered alone at concentration 100 µM, on isolated rat liver microsomes.
Scheme 1 from: Mitkov J, Kondeva-Burdina M, Zlatkov A (2019) Synthesis and preliminary hepatotoxicity evaluation of new caffeine-8-(2-thio)-propanoic hydrazid-hydrazone derivatives. Pharmacia 66(3): 99-106. https://doi.org/10.3897/pharmacia.66.e37263
Scheme 1 General pathway for synthesis of a new caffeine-8-(2-thio)-propanoic hydrazid-hydrazone derivatives 6a–i.
A Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved
<p>Toxicity studies, among them hepatotoxicity, are key throughout preclinical stages of drug development to minimize undesired toxic effects that might later appear during the clinical use of a new drug. Here, we envisage an innovative strategy to identify potential hepatotoxic drugs and uncover the mechanisms of toxicity. This strategy was based on the analysis of metabolome changes induced by hepatotoxic and non-hepatotoxic compounds in HepG2 cells, assessed by untargeted mass spectrometry. As a training set we used 25 hepatotoxic and 4 non-hepatotoxic compounds and incubated HepG2 cells for 24 h at a IC10 and IC50 concentration to identify metabolomic toxicity biomarkers and elaborate prediction models accounting for global hepatotoxicity and toxicity mechanisms. Thereafter, a second set of 69 chemicals with known predominant mechanisms of toxicity and 18 non-hepatotoxic compounds were analysed at 1, 10, 100 and 1000 µM concentrations from which, based on the magnitude of the alterations caused as compared with non-toxic compounds, we defined a “<em>toxicity index</em>” for each compound. In addition we extracted from the metabolome data the characteristic signatures for each mechanism of toxicity.</p>
CYP3A4 and NF-KB gene expression in carbamazepine-induced hepatotoxicity ameliorated by pentoxifylline in rats
Open the record for dataset details and reuse information.
Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia
ClinicalTrials.gov study NCT02373579. IPD Sharing: Not stated. Countries: 0. Publications: 1.
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
ClinicalTrials.gov study NCT04635111. IPD Sharing: YES. Countries: 1. Publications: 0.
Data from: Hepatotoxicity of isotretinoin in patients with acne and Gilbert's syndrome: comparative study
Open the record for dataset details and reuse information.
Phenotypically-anchored transcriptome profiling of developmental exposure to the antimicrobial agent, triclosan, reveals hepatotoxicity in embryonic zebrafish
GEO Series GSE80955. Danio rerio. 8 samples. Type: Expression profiling by array.
Expression profiles of liver tissues from wild-type and AID transgenic mice exposed to thioacetamide hepatotoxicity
GEO Series GSE62878. Mus musculus. 2 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.